Biolargo Stock Price, News & Analysis

BioLargo, Inc. (OTCQB:BLGO) announced the acquisition of EcoMist®, a deodorizing and sanitizing technology, by its subsidiary ONM Environmental. This device installs on waste collection vehicles to spray odor control products during collection, aiming to enhance service for solid waste customers. EcoMist® is easy to install and complements ONM's existing CupriDyne Clean product. The acquisition requires a 10% royalty on sales, aligning with ONM's growth strategy in air quality control. EcoMist® is touted as a unique solution for odor and VOC management.

BioLargo, Inc. (OTCQB:BLGO) announced a significant contract awarded to its subsidiary, BioLargo Engineering, Science & Technologies (BLEST), to aid in the reconfiguration of Regenerative Thermal Oxidizer (RTO) systems at a major East Coast chemical manufacturing plant. This project, linked to a global chemical firm producing phenolic resins, is expected to generate over $500,000 in revenue. The contract's scope may extend over 24 months and involves essential engineering work for energy efficiency improvements.

BioLargo's subsidiary, Clyra Medical Technologies, has launched Clyraguard, a personal disinfectant, on Amazon, enhancing consumer access during the pandemic. The product, with proven 99.999% efficacy against pathogens, is now available for purchase nationwide. Through a partnership with Powerplay Retail, Clyraguard aims to reach major retailers, capitalizing on pandemic demand. The product features eco-friendly ingredients and has received FDA clearance, marking a significant step in making hospital-grade disinfectants accessible to consumers.

Clyra Medical Technologies has launched Clyraguard, a personal disinfectant spray designed for masks and face coverings, now available on Amazon. The product claims to provide a 99.999% antimicrobial efficacy against viruses, including SARS-CoV-2, and received FDA 510(k) clearance. In partnership with Powerplay Retail, Clyraguard will reach major retailers across the U.S., enhancing consumer access. Clyraguard is eco-friendly, alcohol-free, and non-toxic, making it safe for everyday use. This innovative product aims to deliver essential protection amid ongoing pandemic concerns.

BioLargo, Inc. (OTCQB:BLGO) announced record revenues of approximately $650,000 for Q3 2020, a 60% increase from the previous quarter, and about $1.6 million for the nine months ended September 30, 2020, reflecting a 20% year-over-year growth. The company is expanding its supply chain for the Clyraguard product launch, aiming for a capacity of 1,000,000 units monthly. Significant progress in projects related to PFAS treatment is underway, along with new contracts expected to generate substantial revenues. BioLargo's financial health shows improvement with $3.55 million of debt converted to equity.

BioLargo, Inc. (OTCQB:BLGO) announced a significant breakthrough in its CupriDyne technology, demonstrating complete SARS-CoV-2 inactivation in just 10 minutes. This result comes from a third-party study by the Galveston National Laboratory. Previously, the technology achieved 99% reduction of the virus after 30 minutes and full inactivation after 60 minutes. BioLargo plans to apply for EPA registration for a new disinfecting product based on this improved formula. CEO Dennis P. Calvert expressed optimism about the future of these disinfectants, highlighting their effectiveness at lower concentrations than bleach.

BioLargo, Inc. (OTCQB:BLGO) announces its participation in the LD 500 Investor Conference on September 1, 2020, at 8:00 AM PST. CEO Dennis P. Calvert will showcase Clyraguard, an FDA-registered disinfectant for PPE, and discuss the company's innovative PFAS treatment technology. The BioLargo AEC technology is expected to initiate pilots and commercial trials in late 2020, capable of over 99% removal of PFAS contaminants. The conference, running from September 1-4, aims to connect investors with unique capital market opportunities.

BioLargo, Inc. (OTCQB:BLGO) has announced a municipal wastewater treatment pilot for its innovative water treatment technologies, AOS and AEC, to be conducted near Montréal, Québec. This pilot aims to validate the effectiveness and cost-efficiency of these technologies in treating challenging contaminants in real wastewater environments. Funded partly by a $225,000 CAD grant from NSERC, the project is expected to generate initial results by Q1 2021. BioLargo’s technologies previously demonstrated successful wastewater treatment capabilities at a poultry facility in Alberta.

BioLargo, Inc. (OTCQB:BLGO) released its Q2 2020 highlights, coinciding with its 10-Q filing. The company launched Clyraguard, an FDA-registered disinfectant, achieving strong sales growth. It secured a $1 million inventory line and established distribution partnerships. Upcoming projects include a $500,000 revenue-generating AOS water treatment contract and field pilots for PFAS treatment technology. Despite a 2% revenue decrease in Q2, overall revenue rose 8% for the first half of 2020. BioLargo has converted $3.5 million of debt to equity, strengthening its balance sheet.